TK IMPACT: Treatment Monitoring of Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Metastatic Breast Cancer (MBC) Patients Receiving CDK 4/6 Inhibitors (CDK4/6i) with DiviTum® Thymidine Kinase 1 Activity

被引：1
|
作者：
Bagegni, Nusayba A.
Grigsby, Isabella
Nehring, Leslie
Luo, Jingqin
Carson, Jennifer Powers
Gibson, David W.
Horvath, Meghan
Clifton, Katherine K.
Ademuyiwa, Foluso O.
Suresh, Rama
Frith, Ashley
Davis, Andrew A.
Peterson, Lindsay L.
Bose, Ron
Williams, Amy
Bergqvist, Mattias
Ma, Cynthia
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-OT3-11-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-11-01
引用
收藏
页数：3
相关论文
共 50 条
  • [21] HR+/HER2-metastatic Breast Cancer Increasing Data Density of CDK4/6 Inhibitors
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (09) : 485 - 485
  • [22] Cardiovascular disease (CVD) and health care utilization (HCU) in patients (pts) with HR+, HER2 negative (HER2-) advanced breast cancer (ABC) on endocrine therapy with or without CDK4/6 inhibitor (CDK4/6i): A retrospective cohort study
    Dent, S.
    Alder, L.
    Broadwater, G.
    Hyslop, T.
    Oeffinger, K.
    Khouri, M.
    Balu, S.
    Kimmick, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S505 - S506
  • [23] Hormone receptor-positive HER2-low metastatic breast cancer (mBC): evolution of HER2 status after CDK4/6 inhibitor treatment
    de Nonneville, Alexandre
    Finetti, Pascal
    Boudin, Laurys
    Usclade, Lucas
    Mescam, Lenaig
    Durieux, Emeline
    Boucraut, Agathe
    Viret, Frederic
    Mamessier, Emilie
    Goncalves, Anthony
    Bertucci, Francois
    CANCER RESEARCH, 2024, 84 (09)
  • [24] Treatment Strategy for Patients with HR-Positive HER2-Negative Metastatic Breast Cancer That Progressed on CDK4/6 Inhibitors
    Hayama, Shouko
    Nakamura, Rikiya
    Miyaki, Toshiko
    Itami, Makiko
    Yamamoto, Naohito
    BREAST CARE, 2022, 17 (01) : 16 - 23
  • [25] Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer
    Zhang, Cui
    Zhou, Fulin
    Zou, Jiali
    Fang, Yanman
    Liu, Yuncong
    Li, Libo
    Hou, Jing
    Wang, Guanghui
    Wang, Hua
    Lai, Xiaolian
    Xie, Lu
    Jiang, Jia
    Yang, Can
    Huang, Yisidan
    Chen, Yingji
    Zhang, Hanqun
    Li, Yong
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [26] The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.
    Bao, Kelvin K. H.
    Sutanto, Leone
    Tse, Shirley S. W.
    Cheung, Ka Man
    Chan, Jeffrey C. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] CDK4/6-Inhibitors Inclusion in the Treatment of metastatic Hormone Receptor-positive, HER2-negative Breast Cancer
    Forstmeyer, D.
    ONKOLOGE, 2016, 22 (07): : 507 - 508
  • [28] The emerging role of CDK4/6i in HER2-positive breast cancer
    O'Sullivan, Ciara C.
    Suman, Vera J.
    Goetz, Matthew P.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [29] Evolution of prescribing trends for HR+/HER2-metastatic breast cancer (mBC) in a post-CDK4/6i world
    Feinberg, Bruce
    Dokubo, Igoni
    Wojtynek, Jeff
    Kish, Jonathan
    CANCER RESEARCH, 2021, 81 (04)
  • [30] The Effects of HER2 on CDK4/6 Activity in Breast Cancer
    Sinclair, William D.
    Cui, Xiaoyan
    CLINICAL BREAST CANCER, 2022, 22 (03) : E278 - E285
12345